Journal of Leukocyte Biology

J Leukoc Biol. 2026 Mar 20:qiag041. doi: 10.1093/jleuko/qiag041. Online ahead of print. ABSTRACT Tumorigenesis and progression are driven by immune dysregulation and escape, thus evaluating immune function is crucial for the identification of diseases or health conditions. Currently, there is a lack of non-invasive biomarkers in the overall management of PCa to assess a patient’s … Read more

J Leukoc Biol. 2026 Mar 17:qiag036. doi: 10.1093/jleuko/qiag036. Online ahead of print. ABSTRACT Dysregulated inflammation in response to inciting events leads to severe end-organ dysfunction and failure, contributing to long-term morbidity and ultimately potentially death. Duffy Associated Receptor for Chemokines (DARC), a major regulator of inflammation, play key roles in a variety of acute and … Read more

J Leukoc Biol. 2026 Mar 16:qiag035. doi: 10.1093/jleuko/qiag035. Online ahead of print. ABSTRACT Antigen presentation via MHC class I molecules (MHC-Is) is a turning point in the establishment of immune responses to endogenous threats, such as viruses. From their synthesis to their cell surface display, MHC-Is travel to many compartments, including the ER, Golgi, and … Read more

J Leukoc Biol. 2026 Mar 14:qiag038. doi: 10.1093/jleuko/qiag038. Online ahead of print. ABSTRACT Central tolerance in the thymus is orchestrated by the autoimmune regulator (Aire), which enables medullary thymic epithelial cells (mTECs) to express tissue-restricted antigens (TRAs) and present them to developing T cells via MHC-II molecules. While Aire’s role in mTEC heterogeneity is well … Read more

J Leukoc Biol. 2026 Mar 11:qiag034. doi: 10.1093/jleuko/qiag034. Online ahead of print. ABSTRACT Macrophages are on the front lines against viral infections and play a central role in initiating antiviral immune responses. They do this by sensing viral ligands through their arsenal of pattern recognition receptors, which fine-tune and determine the specificity of the immune … Read more

J Leukoc Biol. 2026 Mar 9:qiag032. doi: 10.1093/jleuko/qiag032. Online ahead of print. ABSTRACT High grade serous carcinoma (HGSC) of the ovary remains the deadliest gynecologic cancer, with five-year survival rates of less than 50%. Remission is usually achieved by surgical debulking and chemotherapy, but most (∼70%) of patients ultimately develop treatment-resistant disease. Infiltration of immune … Read more

J Leukoc Biol. 2026 Mar 3;118(3):qiag021. doi: 10.1093/jleuko/qiag021. ABSTRACT Liver fibrosis is a chronic condition that often leads to organ failure. Currently, no effective treatment exists for advanced liver fibrosis. De-repression of the transcription factor Nrf2, by inhibition of the ubiquitin ligase substrate adaptor Keap1, is a promising strategy to treat liver fibrosis because Nrf2 … Read more

J Leukoc Biol. 2026 Mar 3:qiag030. doi: 10.1093/jleuko/qiag030. Online ahead of print. ABSTRACT In NSCLC, radiotherapy mediates cytotoxicity but also activates radioresistance drivers like HER2. We investigated radiotherapy combined with HER2-targeted T cell therapy in a NSCLC model. The anti-tumor efficacy of radiotherapy and engineered T cells expressing a DAP12-associated synthetic antigen receptor (SAR) targeting … Read more

J Leukoc Biol. 2026 Feb 27:qiag025. doi: 10.1093/jleuko/qiag025. Online ahead of print. ABSTRACT Besides their largely specific and abundant toxic granule proteins, their Charcot-Leyden crystals, DNA traps, and the release of leukotrienes, human eosinophils are often seen as affecting the immune response and tissue remodeling due to the release of numerous types of cytokines and … Read more

J Leukoc Biol. 2026 Feb 28:qiag029. doi: 10.1093/jleuko/qiag029. Online ahead of print. NO ABSTRACT PMID:41761660 | DOI:10.1093/jleuko/qiag029